New York, October 24, 2024 - PRISM MarketView - Just ahead of Movember, the annual movement to raise awareness of men’s health issues, LifeMD, Inc. (Nasdaq: LFMD) has introduced TestoRx, a new testosterone replacement therapy (TRT) offering through its Rex MD men’s health platform. This telehealth service broadens Rex MD’s offerings by addressing male hypogonadism, a condition where the body produces low levels of testosterone, affecting millions of men, particularly those over 45 or with obesity and type 2 diabetes.
“We are pleased to introduce this new testosterone therapy clinical offering as part of our Rex MD men’s health services. TestoRx was designed in partnership with clinicians renowned in their field to ensure a highly compliant protocol with multiple treatment approaches focused on men with clinically low testosterone. Our goal is to provide a convenient and affordable solution to improve hormonal health for men in the comfort of their own home.”
Justin Schreiber, Chairman and CEO
TestoRx includes an initial consultation, pre-screening blood tests, and offers both testosterone replacement therapy and alternative treatments to stimulate natural hormone production. The program also provides ongoing telehealth visits and follow-up care. This new addition complements Rex MD’s existing services, which include treatments for erectile dysfunction, hair loss, and weight management, providing men with a convenient, at-home solution to improve hormonal health.
The Company is scheduled to report its third quarter 2024 financial results on Nov. 7th.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities